ALNY

Alnylam Pharmaceuticals
D

ALNY

325.26
USD
-4.39
(-1.33%)
مغلق
حجم التداول
20,513
الربح لكل سهم
0
العائد الربحي
-
P/E
-155
حجم السوق
42,410,128,707
أصول ذات صلة
A
ARWR
-0.120
(-0.71%)
16.790 USD
BMRN
BMRN
0.560
(0.98%)
57.750 USD
C
CRSP
0.455
(0.88%)
52.120 USD
E
EDIT
0.02000
(0.78%)
2.57000 USD
GILD
GILD
-0.760
(-0.68%)
110.760 USD
INCY
INCY
0.300
(0.44%)
68.470 USD
I
IONS
-0.450
(-1.03%)
43.190 USD
REGN
REGN
-0.69
(-0.13%)
546.88 USD
S
SGMO
0.00200
(0.38%)
0.53200 USD
VRTX
VRTX
2.24
(0.49%)
459.27 USD
المزيد
الأخبار المقالات

العنوان: Alnylam Pharmaceuticals

القطاع: Healthcare
الصناعة: Biotechnology
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.